The objectives of this study were to provide individual and population-based unit cost estimates of HIV treatment and care by stage of HIV infection for adults in England and estimate the financial impact of the use of combination antiretroviral therapy.
Individual unit cost estimates were calculated, based on 1997 activity data, and linked to the number of diagnosed HIV-infected individuals using statutory medical services by clinical stage of HIV infection in England during 1997 to obtain population-based cost estimates ; these were compared with 1996 estimates.
Most clinical guidelines now recommend the use of 3 antiretroviral agents, but cost estimates for mono and dual therapy were included as baseline estimates.
Baseline costs for treating AIDS patients with zidovudine (AZT) monotherapy were estimated at £16,830 (95% CI 14,633-18,985) per patient-year which was substantially lower than the 1996 estimate ; costs for asymptomatic individuals and people with symptomatic non-AIDS were £4450 (95% CI 3521-5612) and £7289 (95% CI 6169-8386) per respective patient-year which did not differ substantially from 1996.
The total annual population cost estimate for HIV service provision amounted to £128 million (95% CI £109m to £147m), if all patients with HIV disease were treated with AZT monotherapy only. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Traitement, Antiviral, Association médicamenteuse, Coût, Estimation, Stade clinique, Etude comparative, Protocole thérapeutique, Angleterre, Grande Bretagne, Royaume Uni, Europe, Homme, Immunopathologie, Immunodéficit, Economie santé
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Treatment, Antiviral, Drug combination, Costs, Estimation, Clinical stage, Comparative study, Therapeutic protocol, England, Great Britain, United Kingdom, Europe, Human, Immunopathology, Immune deficiency, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0359231
Code Inist : 002B05C02D. Création : 14/12/1999.